Windtree Therapeutics competitors

Experienced public company CEO determined to leave the world a healthier place than when he arrived by developing new treatments for serious diseases and conditions.

Mr. Onsi has served as our Chief Financial Officer, Treasurer and Secretary since our inception in 2011. Mr. Onsi has been at HealthCare Ventures since 2007, including serving as a managing director since 2009 and the chief executive officer of Tensha Therapeutics, Inc. which was sold to Roche Holdings, Inc. in 2016. Prior to joining HealthCare Ventures, Mr. Onsi was at Genzyme Corporation, or Genzyme, where he served in roles as Vice President, Campath Product Operations and Portfolio Management, Oncology from 2005 to 2007 and as Vice President, Business Development from 2004 to 2005. Prior to Genzyme, he was Chief Financial Officer of Tolerx, Inc., a venture capital funded biotechnology company, from 2001 to 2004. Before joining Tolerx, Inc., he was in business development at LeukoSite, a publicly traded biopharmaceutical company that was acquired by Millennium Pharmaceuticals, Inc. He began his career as an attorney at Bingham Dana LLP. Mr. Onsi currently serves as a member of the board of directors of Vaxxas Pty Ltd., a privately-held biotechnology company. He received a Juris Doctor degree from the University of Michigan Law School and a B.S. in biological sciences from Cornell University.

John Kollins is a President/CEO/Co-Founder at SATSUMA PHARMACEUTICALS INC, Board Member at SATSUMA PHARMACEUTICALS INC, and Advisor at Covx and is based in South San Francisco, California. He has experience at ATHENA NEUROSCIENCES INC and Elan Pharmaceutical and has worked as Chief Operating Officer at Oxigene Inc, Vice President at SurroMed, and Advisor To CEO at SurroMed. John works or has worked as Consultant at Covx, CHAIRMAN at CovX Research LLC, and Consultant at Entelos. He studied at Duke University between 1981 and 1985 and University of Virginia Darden School of Business between 1987 and 1989.

As a senior executive with 20+ years of sell- and buy- side business and corporate development experience, my career encompasses roles in therapeutics, biotech, genomics, medical devices, and pharmacy benefits. During my tenure at Pfizer, I completed more than 2 dozen acquisition, co-development, and licensing deals ranging from $300M to $7B. Later at Foundation Medicine, I led the $1B sale of their genomics testing to Roche, and earlier played a leadership role in Medco’s $29B sale to Express Scripts. I have worked extensively within R&D environments and launched 3 $1B+ therapeutic products in the hypertension and antibiotics categories. Additionally, I have been the CEO of early stage start-ups, building the funding, commercialization, and exit strategy for therapeutics companies in the CNS and autoimmune disease space.Currently, as CEO of Cognition Therapeutics, I am driving Series C fundraising effort. With multiple phase 2 clinical trials well under way for the Alzheimer’s research and more than a hundred million dollars in dedicated funding, I am repositioning the company to broaden the focus on our science and other CNS clinical conditions. I am pleased to lead a company dedicated to halting neurological disease processes and restoring and preserving the building blocks of brain health and function and look forward to sharing our progress here.